Can these weight loss drugs help with PR?

ahsan65@gmail.comJuly 28, 2025

0 0 2 minutes read

Can these weight loss drugs help with PR?

In theory, GLP-1 should improve the symptoms of PR. Additional body fat creates additional inflammation, including joint inflammation.

But studies are necessary to prove whether the GLP-1 improve the symptoms of PR and the activity of the disease, explains Karacabeyli.

“To date, there are no research articles over the entire length describing the changes in the activity of PR after treatment with agonists from GLP-1 receptors,” he said.

Ra joint symptoms

Although the evidence is limited, laboratory studies are promising. GLP-1 drugs seem to reduce inflammation in a way that is not directly linked to weight loss, such as helping to block a key inflammatory track called NF-KB, which is involved in joint lesions and activation of the immune system in PR. Although the anti-inflammatory effect has been observed in PR models, it is not yet clear if this results in a significant relief of symptoms in patients in the real world.

There is also evidence, including a study of people with obesity and osteoarthritis New England Journal of MedicineThat GLP-1 can help with other types of arthritis, explains Lane.

“They found a huge reduction in pain and weight loss in the group that has taken semaglutide (Wegovy). It turned out to be the most effective analgesic for osteoarthritis that we have ever had to date, ”explains Lane.

But Lane and Karacabeyli agree that what is really necessary are well -designed clinical trials in people with PR to find out if these drugs really reduce the activity of the disease.

RA Comorbidities, like heart disease

What is clear is that GLP-1 helps manage common comorbid conditions in PR, such as obesity, diabetes and heart disease. These conditions tend to aggravate PR and are also more frequent in people with the general population – people with PR are 50 to 70% more likely to have heart disease than the general population.

In overweight or obesity, Wegovy has been approved to reduce the risk of cardiovascular death, heart attack and stroke.

Karacabeyli and his colleagues conducted a study (subject for publication but not yet published) by comparing GLP-1 drugs with another diabetes treatment in people with immune mediation diseases, including Pr.

“A subgroup analysis revealed that GLP-1 users with PR had fewer heart attacks, cerebral vascular accidents and deaths caused by cardiovascular causes of those under a different diabetes drug.

ahsan65@gmail.comJuly 28, 2025

0 0 2 minutes read